Triple Frontiers
Topic

GLP-1

Retrospective · Markets

Novo v Lilly: how the weight-loss drug race turned, from profit warnings to pills

Novo Nordisk cut its forecasts, replaced its chief executive and shed 9,000 jobs as Eli Lilly became the first drugmaker worth $1 trillion. A US pricing deal, generic semaglutide in India and new daily pills followed, and by November 2026 Novo had raised its outlook on oral Wegovy sales.

By Business Desk · Events of Jul 2025 · 6 min read

Stay with Triple Frontiers

Latest across Triple Frontiers

All latest news